Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108953 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT00108953: Completed Phase 2 study, sponsored by Bayer.
NCT00108953 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 96 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00108953, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
Primary Outcome
TTP was defined as the time from randomization to radiological disease progression by independent assessment.
Interventions
- DRUG Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
- DRUG Doxorubicin/Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
What the finished NCT00108953 record still lists
NCT00108953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 2 interventions - of which Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin is the first listed.
NCT00108953 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00108953 about?
NCT00108953 is a clinical study titled "A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma". The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
What is the current status of trial NCT00108953?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2005-04. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00108953?
The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin (DRUG), Doxorubicin/Placebo (DRUG).
Who is sponsoring clinical trial NCT00108953?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00108953's enrollment target sits among peer trials
96 747th of 2000 higher than 1,242 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia